<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17560</article-id><article-id pub-id-type="doi">10.15789/2220-7619-TIO-17560</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE IMPACT OF CONCOMITANT DISEASES DURING SARS-COV-2 INFECTION IN RESIDENTS OF KAZAKHSTAN</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ СОПУТСТВУЮЩИХ ЗАБОЛЕВАНИЙ ПРИ ИНФЕКЦИИ SARS-COV-2 У ЖИТЕЛЕЙ КАЗАХСТАНА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ashirova</surname><given-names>Mayra Zangarovna</given-names></name><name xml:lang="ru"><surname>Аширова</surname><given-names>Майра Зангаровна</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>3rd year doctoral student, assistant at the Department of Infectious Diseases and Dermatovenereology </p></bio><bio xml:lang="ru"><p>докторант 3 курса, ассистент кафедры инфекционных болезней и дерматовенерологии </p></bio><email>mayra.ashirova@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1210-2018</contrib-id><name-alternatives><name xml:lang="en"><surname>Abuova</surname><given-names>Gulzhan Narkenovna</given-names></name><name xml:lang="ru"><surname>Абуова</surname><given-names>Гульжан Наркеновна</given-names></name></name-alternatives><address><country country="KZ">Kazakhstan</country></address><bio xml:lang="en"><p>head of the department of infectious diseases and dermatovenereology</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, профессор, заведующая кафедрой инфекционных болезней и дерматовенерологии </p></bio><email>dr.abuova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Seytkhanova</surname><given-names>Bibigul  Toelegenovna</given-names></name><name xml:lang="ru"><surname>Сейтханова</surname><given-names>Бибигуль  Тоелегеновна</given-names></name></name-alternatives><bio xml:lang="en"><p>Candidate of Medical Sciences, Head of the Department of Microbiology, </p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, заведующая кафедрой микробиологии </p></bio><email>d.m.n._bibigul@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">South Kazakhstan Medical Academy, Shymkent, Kazakhstan</institution></aff><aff><institution xml:lang="ru">Южно-Казахстанская медицинская академия, Шымкент, Казахстан</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-11-14" publication-format="electronic"><day>14</day><month>11</month><year>2024</year></pub-date><history><date date-type="received" iso-8601-date="2023-12-22"><day>22</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-10-27"><day>27</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Ashirova M.Z., Abuova G.N., Abuova G.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Ashirova M., Abuova G., Abuova G.</copyright-statement><copyright-holder xml:lang="en">Ashirova M.Z., Abuova G.N., Abuova G.N.</copyright-holder><copyright-holder xml:lang="ru">Ashirova M., Abuova G., Abuova G.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/17560">https://iimmun.ru/iimm/article/view/17560</self-uri><abstract xml:lang="en"><p>Background . Since the onset of the COVID -19 pandemic, interindividual variability in the course of the disease has been reported , indicating a wide range of factors influencing it. Factors most commonly associated with increased severity of COVID -19 disease include older age, obesity, and diabetes. The impact of the cytokine storm is complex, reflecting the complexity of the immunological processes triggered by SARS - CoV -2 infection. A modern problem such as a worldwide pandemic requires modern solutions, which in this case involve the use of machine learning to analyze differences in the clinical properties of populations affected by the disease and then assess its significance, which in turn leads to the creation of a tool that applicable to assess the individual risk of infection with SARS - CoV -2.</p> <p>Methods . Values of biochemical and morphological parameters of 781 patients ( Kazakhstan, Shymkent ) were collected and used for static analysis. The Spearman rank correlation coefficient formula was used to estimate the correlations between each of the traits in the population .</p> <p>Results . The highest correlation coefficients were shown by such parameters as , patient's age and sex , serum glucose, while the highest inverse correlation coefficient was estimated for serum red blood cell count.</p> <p>Conclusion . The current analysis indicates a range of parameters available for routine screening in clinical settings. A tool based on these parameters is also presented, useful for assessing the individual risk of developing COVID -19 in patients. A limitation of the study is the demographics of the study population, which may limit its general applicability.</p></abstract><trans-abstract xml:lang="ru"><p>История вопроса. С начала пандемии COVID-19 сообщалось о межиндивидуальных особенностях течения заболевания, что указывает на широкий спектр факторов, влияющих на него. Факторы, наиболее часто связанные с повышенной тяжестью заболевания COVID-19 включают пожилой возраст, ожирение и диабет. Цитокиновый шторм оказывает разные эффекты, что отражает сложность иммунологических процессов, запускаемых инфекцией SARS-CoV-2. Вызовы современности, такие как глобальные пандемии, требуют новых решений, которые могут включать использование машинного обучения для анализа различий в клинических свойствах популяций пациентов и последующей оценки его значимости, что, в свою очередь, приводит к созданию инструмента для оценки индивидуального риска заражения SARS-CoV-2.</p> <p>Методы. Значения биохимических и морфологических параметров 781 пациента (Казахстан, Шымкент) были собраны и использованы для статического анализа. Формула коэффициента ранговой корреляции Спирмена использовалась для оценки корреляций между каждым из признаков в популяции.</p> <p>Результаты. Самые высокие коэффициенты корреляции были показаны для таких параметров, как возраст и пол пациента, уровень глюкозы в сыворотке, в то время как самый высокий коэффициент обратной корреляции был обнаружен для содержания эритроцитов в сыворотке крови.</p> <p>Заключение. Представленный анализ указывает на ряд параметров, доступных для рутинного скрининга в клинических условиях. Также представлен подход, основанный на изученных параметрах, применимый для оценки индивидуального риска развития COVID-19 у пациентов. Ограничением исследования является демографическая характеристика исследуемой популяции, что может влиять на его общую применимость.</p></trans-abstract><kwd-group xml:lang="en"><kwd>SARS - CoV -2</kwd><kwd>blood biomarkers</kwd><kwd>COVID -19</kwd><kwd>comorbid pathology</kwd><kwd>arterial hypertension.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>SARS-CoV-2</kwd><kwd>биомаркеры крови</kwd><kwd>COVID-19</kwd><kwd>коморбидная патология</kwd><kwd>артериальная гипертензия.</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Al Argan R, Alkhafaji D, Al Elq A, Albaker W, Alqatari S, Alzaki A, Alwaheed A, Al Said A, Bukhari H, Al Warthan S, Zeeshan M, AlRubaish F, AlElq Z, Alsahlawi A, Alalwan M, AlHwiesh A, Alabdrabalnabi FI. The Impact of Diabetes Mellitus and Hyperglycemia on the Severity and Outcome of Patients with COVID-19 Disease: A Single-Center Experience. Int J Gen Med. 2021 Dec 6;14:9445-9457. doi: 10.2147/IJGM.S338800. PMID: 34908871; PMCID: PMC8664338.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Guerreiro SG, Cruz-Martins N, Batiha GE. COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus. Front Cardiovasc Med. 2021 May 20;8:644095. doi: 10.3389/fcvm.2021.644095. PMID: 34124187; PMCID: PMC8189260.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2020 Dec 9:1-12. doi: 10.1159/000512592. Epub ahead of print. PMID: 33296901; PMCID: PMC7801974.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091. Erratum in: BMJ. 2020 Mar 31;368:m1295. doi: 10.1136/bmj.m1295. PMID: 32217556; PMCID: PMC7190011.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, Bonora BM, Selmin E, Arcidiacono G, Pinelli S, Farnia F, Falaguasta D, Russo L, Voltan G, Mazzocut S, Costantini G, Ghirardini F, Tresso S, Cattelan AM, Vianello A, Avogaro A, Vettor R. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Oct;168:108374. doi: 10.1016/j.diabres.2020.108374. Epub 2020 Aug 15. PMID: 32805345; PMCID: PMC7428425.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front Endocrinol (Lausanne). 2021 Jun 17;12:649525. doi: 10.3389/fendo.2021.649525. PMID: 34220706; PMCID: PMC8247904.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29. PMID: 32474009; PMCID: PMC7256510.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020 Dec;23(5):1416-1424. doi: 10.1080/13685538.2020.1774748. Epub 2020 Jun 8. PMID: 32508193.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Rahman MA, Shanjana Y, Tushar MI, Mahmud T, Rahman GMS, Milan ZH, Sultana T, Chowdhury AMLH, Bhuiyan MA, Islam MR, Reza HM. Hematological abnormalities and comorbidities are associated with COVID-19 severity among hospitalized patients: Experience from Bangladesh. PLoS One. 2021 Jul 27;16(7):e0255379. doi: 10.1371/journal.pone.0255379. PMID: 34314447; PMCID: PMC8315496.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Sun Y, Koh V, Marimuthu K, Ng OT, Young B, Vasoo S, Chan M, Lee VJM, De PP, Barkham T, Lin RTP, Cook AR, Leo YS; National Centre for Infectious Diseases COVID-19 Outbreak Research Team. Epidemiological and Clinical Predictors of COVID-19. Clin Infect Dis. 2020 Jul 28;71(15):786-792. doi: 10.1093/cid/ciaa322. PMID: 32211755; PMCID: PMC7542554.</mixed-citation></ref></ref-list></back></article>
